Evidence map›Paper›PMID 30762153›Full record

ArticleEndocrine2019

Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.

Silvia Cantara, Eugenio Bertelli, Rossella Occhini, Marì Regoli, Lucia Brilli, Furio Pacini, Maria Grazia Castagna, Paolo Toti

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. [Personalized approach to anaplastic thyroid carcinoma].Chirurgie (Heidelberg, Germany) · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Silvia CantaraDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy. cantara@unisi.it.ORCID 0000-0002-5741-295X
Eugenio BertelliDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Rossella OcchiniUnit of Pathology, Arezzo Hospital, Arezzo, Italy.
Marì RegoliDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Lucia BrilliDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Furio PaciniDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Maria Grazia CastagnaDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Paolo TotiUniversity of Siena, Siena, Italy.
University of Siena · ITAzienda Usl 8 Arezzo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnaplastic thyroid carcinoma (ATC) is a rare, highly aggressive form of thyroid cancer (TC) characterized by an aggressive behavior and poor prognosis, resulting in patients' death within a year. Standard treatments, such as chemo and radiotherapy, as well as tyrosine kinase inhibitors, are ineffective for ATC treatment. Cancer immunotherapy is one of the most promising research area in oncology. The PD-1/PD-L1 axis is of particular interest, in light of promising data showing a restoration of host immunity against tumors, with the prospect of long-lasting remissions.

methodsIn this study, we evaluated PD-L1 expression in a large series of TCs (20 cases) showing a progressive dedifferentiation of the thyroid tumor from well differentiated TC to ATC, employing two different antibodies [R&D Systems and VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody]. We also tested the anti PD-L1 mAb in an in vivo animal model.

resultsWe found that approximately 70-90% of ATC cases were positive for PD-L1 whereas normal thyroid and differentiated TC were negative. Moreover, all analyzed cases presented immunopositive staining in the endothelium of vessels within or in close proximity to the tumor, while normal thyroid vessels were negative. PD-L1 mAb was also effective in inhibiting ATC growth in an in vivo model.

conclusionsThese data suggest that immunotherapy may be a promising treatment specific for ATC suggesting the need to start with clinical TRIALs.

Indexed as

AdultAgedAged, 80 and overAnimalsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCell Line, TumorFemaleHumansMaleMiceMiddle AgedThyroid Carcinoma, AnaplasticThyroid NeoplasmsTreatment OutcomeAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanAnaplastic thyroid cancerImmunotherapyPD-1PD-L1

Identifiers

PMID30762153
OpenAlexW2915045264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.